{"nctId":"NCT01109173","briefTitle":"Confirmatory Study Nepafenac 0.3%","startDateStruct":{"date":"2010-06"},"conditions":["Cataract"],"count":2120,"armGroups":[{"label":"Nepafenac 0.3%","type":"EXPERIMENTAL","interventionNames":["Drug: Nepafenac Ophthalmic Suspension, 0.3%"]},{"label":"NEVANAC","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nepafenac Ophthalmic Suspension, 0.1%"]},{"label":"Nepafenac Vehicle 0.3%","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Nepafenac Ophthalmic Suspension 0.3% Vehicle"]},{"label":"NEVANAC Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Other: NEVANAC Vehicle"]}],"interventions":[{"name":"Nepafenac Ophthalmic Suspension, 0.3%","otherNames":[]},{"name":"Nepafenac Ophthalmic Suspension, 0.1%","otherNames":["NEVANACÂ®"]},{"name":"Nepafenac Ophthalmic Suspension 0.3% Vehicle","otherNames":[]},{"name":"NEVANAC Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Planned cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens;\n* Patients who, in the opinion of the Investigator, would have improvement in best-corrected visual acuity after surgery;\n* Able to understand and sign an informed consent;\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Use of topical ocular, inhaled or systemic nonsteroidal anti-inflammatory drugs within 7 days of surgery, with the exception of the allowed low dose of aspirin (up to 100 mg) prior to surgery and through study exit;\n* Use of topical ocular, inhaled or systemic steroids within 14 days prior to surgery and through study exit;\n* History of chronic or recurrent inflammatory eye disease (eg, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the operative eye;\n* Diabetic retinopathy in the operative eye;\n* Known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article;\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Cured at Day 14","description":"Ocular inflammation was assessed by the investigator during slit lamp examination. Aqueous cells were scored on a 5-unit scale from 0 (none) to 4 (\\> 30 cells), and aqueous flare (protein escaping from dilated vessels) was scored on a 4-unit scale from 0 (no visible flare when compared with the normal eye) to 3 (severe - very dense flare). To be considered cured, the patient must have had a score of 0 for both cells and flare.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"70.0","spread":null},{"groupId":"OG002","value":"34.0","spread":null},{"groupId":"OG003","value":"35.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Pain-Free at Day 14","description":"Ocular pain as assessed by the investigator on a scale ranging from 0 (none) to 5 (severe). Pain-free was defined as a score of 0 on the investigator's assessment of ocular pain.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"90.9","spread":null},{"groupId":"OG002","value":"49.7","spread":null},{"groupId":"OG003","value":"56.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":817},"commonTop":[]}}}